Oppenheimer & Co’s Novavax NVAX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $856K | Buy |
105,168
+69,357
| +194% | +$629K | 0.01% | 939 |
|
|
2025
Q4 | $241K | Sell |
35,811
-38,132
| -52% | -$287K | ﹤0.01% | 1360 |
|
|
2025
Q3 | $641K | Buy |
73,943
+5,391
| +8% | +$42K | 0.01% | 1090 |
|
|
2025
Q2 | $432K | Buy |
68,552
+17,814
| +35% | +$118K | 0.01% | 1195 |
|
|
2025
Q1 | $325K | Buy |
50,738
+7,165
| +16% | +$59.2K | ﹤0.01% | 1234 |
|
|
2024
Q4 | $350K | Buy |
43,573
+31,559
| +263% | +$304K | 0.01% | 1195 |
|
|
2024
Q3 | $152K | Buy |
12,014
+370
| +3% | +$4.78K | ﹤0.01% | 1435 |
|
|
2024
Q2 | $147K | Sell |
11,644
-475
| -4% | -$4.78K | ﹤0.01% | 1370 |
|
|
2024
Q1 | $57.9K | Sell |
12,119
-2,570
| -17% | -$11.9K | ﹤0.01% | 1407 |
|
|
2023
Q4 | $70.5K | Sell |
14,689
-1,678
| -10% | -$10.3K | ﹤0.01% | 1345 |
|
|
2023
Q3 | $118K | Sell |
16,367
-2,750
| -14% | -$22K | ﹤0.01% | 1311 |
|
|
2023
Q2 | $142K | Sell |
19,117
-4,550
| -19% | -$35.8K | ﹤0.01% | 1328 |
|
|
2023
Q1 | $164K | Sell |
23,667
-600
| -2% | -$5.52K | ﹤0.01% | 1284 |
|
|
2022
Q4 | $249K | Sell |
24,267
-9,721
| -29% | -$172K | 0.01% | 1153 |
|
|
2022
Q3 | $619K | Sell |
33,988
-20,664
| -38% | -$895K | 0.01% | 816 |
|
|
2022
Q2 | $2.81M | Sell |
54,652
-4,950
| -8% | -$256K | 0.06% | 362 |
|
|
2022
Q1 | $4.39M | Buy |
59,602
+15,452
| +35% | +$1.38M | 0.08% | 298 |
|
|
2021
Q4 | $6.32M | Buy |
44,150
+14,197
| +47% | +$2.44M | 0.11% | 215 |
|
|
2021
Q3 | $6.21M | Buy |
29,953
+24,892
| +492% | +$5.49M | 0.12% | 196 |
|
|
2021
Q2 | $1.07M | Sell |
5,061
-666
| -12% | -$122K | 0.02% | 719 |
|
|
2021
Q1 | $1.04M | Buy |
5,727
+1,730
| +43% | +$345K | 0.02% | 696 |
|
|
2020
Q4 | $446K | Buy |
3,997
+137
| +4% | +$14.6K | 0.01% | 939 |
|
|
2020
Q3 | $418K | Sell |
3,860
-4,057
| -51% | -$494K | 0.01% | 873 |
|
|
2020
Q2 | $660K | Sell |
7,917
-20,266
| -72% | -$775K | 0.02% | 702 |
|
|
2020
Q1 | $382K | Buy |
+28,183
| New | +$238K | 0.01% | 821 |
|
|
2019
Q2 | – | Sell |
-3,602
| Closed | -$40K | – | 1361 |
|
|
2019
Q1 | $40K | Buy |
+3,602
| New | +$114K | ﹤0.01% | 1328 |
|
|
2018
Q1 | – | Sell |
-500
| Closed | -$13K | – | 1373 |
|
|
2017
Q4 | $13K | Sell |
500
-279
| -36% | -$6.81K | ﹤0.01% | 1307 |
|
|
2017
Q3 | $18K | Sell |
779
-150
| -16% | -$3.36K | ﹤0.01% | 1284 |
|
|
2017
Q2 | $21K | Buy |
+929
| New | +$18.2K | ﹤0.01% | 1287 |
|
|
2014
Q2 | – | Sell |
-838
| Closed | -$75K | – | 1456 |
|
|
2014
Q1 | $75K | Buy |
838
+38
| +5% | +$4.25K | ﹤0.01% | 1362 |
|
|
2013
Q4 | $82K | Hold |
800
| – | – | ﹤0.01% | 1331 |
|
|
2013
Q3 | $50K | Sell |
800
-1,300
| -62% | -$73.2K | ﹤0.01% | 1282 |
|
|
2013
Q2 | $86K | Buy |
+2,100
| New | +$91K | ﹤0.01% | 1200 |
|
Other funds holding NVAX
SCM
VPM
VCM
S
Oppenheimer & Co's NVAX Position: Q1 2026 in Review
Oppenheimer & Co increased its Novavax (NVAX) stake by 194% in Q1 2026, buying an estimated $629K and bringing the position to 105,168 shares worth $856K. The position accounts for 0.01% of the portfolio, ranked #939.
Oppenheimer & Co first reported a position in NVAX in Q2 2013 and has held it in 33 quarters since. The position peaked at $6.32M in Q4 2021. 258 funds tracked by Wall St. Rank hold NVAX as of Q1 2026.
- Oppenheimer & Co held 105,168 shares of Novavax worth $856K as of Q1 2026.
- Oppenheimer & Co bought 69,357 Novavax shares in Q1 2026, an estimated $629K.
- Novavax made up 0.01% of Oppenheimer & Co's portfolio in Q1 2026, its #939 holding.
- Oppenheimer & Co first reported a position in Novavax in Q2 2013 and has held it in 33 quarters since.
- Oppenheimer & Co's Novavax position peaked at $6.32M in Q4 2021.
- 258 funds tracked by Wall St. Rank held Novavax as of Q1 2026.
Based on Oppenheimer & Co's 13F filing for Q1 2026, filed 24 Apr 2026.